Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Patrick Reynolds

Showing results (51-60 of 212) with videos related to

Pageof 22
Sort By:
Addictive Behaviors|September 28, 2010
Increased self-efficacy to quit and perceived control over withdrawal symptoms predict smoking cessation following nicotine dependence treatmentRobert A Schnoll, Elisa Martinez, Kristina L Tatum, et al.
Pediatric Blood & Cancer|October 30, 2013
Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing programRaushan T Kurmasheva, C Patrick Reynolds, Min H Kang, et al.
Cancer Immunology, Immunotherapy : CII|February 26, 2015
Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastomaDiana Seidel, Anastasia Shibina, Nikolai Siebert, et al.
Pediatric Blood & Cancer|October 6, 2010
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testingMin H Kang, Malcolm A Smith, Christopher L Morton, et al.
Molecular Cancer Therapeutics|October 14, 2003
Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell linesHiroaki Goto, Bo Yang, Denise Petersen, et al.
Cancer Research|June 18, 2003
Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonateYasuyoshi Sohara, Hiroyuki Shimada, Miriam Scadeng, et al.
Cancers|February 13, 2021
Neuroblastoma Invasion Strategies Are Regulated by the Extracellular MatrixCian Gavin, Nele Geerts, Brenton Cavanagh, et al.
Pediatric Blood & Cancer|September 19, 2017
Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing ProgramRaushan T Kurmasheva, Dias Kurmashev, C Patrick Reynolds, et al.
British Journal of Pharmacology|July 22, 2014
Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastomaPoonam Sonawane, Hwang Eui Cho, Ashujit Tagde, et al.
Anti-Cancer Drugs|December 16, 2020
The O6-methyguanine-DNA methyltransferase inhibitor O6-benzylguanine enhanced activity of temozolomide + irinotecan against models of high-risk neuroblastomaAshly Hindle, Balakrishna Koneru, Monish Ram Makena, et al.
Pageof 22

Showing results (51-60 of 212) with videos related to

Sort By:
Pageof 22
Addictive Behaviors|September 28, 2010
Increased self-efficacy to quit and perceived control over withdrawal symptoms predict smoking cessation following nicotine dependence treatmentRobert A Schnoll, Elisa Martinez, Kristina L Tatum, et al.
Pediatric Blood & Cancer|October 30, 2013
Initial testing (stage 1) of the topoisomerase II inhibitor pixantrone, by the pediatric preclinical testing programRaushan T Kurmasheva, C Patrick Reynolds, Min H Kang, et al.
Cancer Immunology, Immunotherapy : CII|February 26, 2015
Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastomaDiana Seidel, Anastasia Shibina, Nikolai Siebert, et al.
Pediatric Blood & Cancer|October 6, 2010
National Cancer Institute pediatric preclinical testing program: model description for in vitro cytotoxicity testingMin H Kang, Malcolm A Smith, Christopher L Morton, et al.
Molecular Cancer Therapeutics|October 14, 2003
Transduction of green fluorescent protein increased oxidative stress and enhanced sensitivity to cytotoxic drugs in neuroblastoma cell linesHiroaki Goto, Bo Yang, Denise Petersen, et al.
Cancer Research|June 18, 2003
Lytic bone lesions in human neuroblastoma xenograft involve osteoclast recruitment and are inhibited by bisphosphonateYasuyoshi Sohara, Hiroyuki Shimada, Miriam Scadeng, et al.
Cancers|February 13, 2021
Neuroblastoma Invasion Strategies Are Regulated by the Extracellular MatrixCian Gavin, Nele Geerts, Brenton Cavanagh, et al.
Pediatric Blood & Cancer|September 19, 2017
Initial testing (stage 1) of M6620 (formerly VX-970), a novel ATR inhibitor, alone and combined with cisplatin and melphalan, by the Pediatric Preclinical Testing ProgramRaushan T Kurmasheva, Dias Kurmashev, C Patrick Reynolds, et al.
British Journal of Pharmacology|July 22, 2014
Metabolic characteristics of 13-cis-retinoic acid (isotretinoin) and anti-tumour activity of the 13-cis-retinoic acid metabolite 4-oxo-13-cis-retinoic acid in neuroblastomaPoonam Sonawane, Hwang Eui Cho, Ashujit Tagde, et al.
Anti-Cancer Drugs|December 16, 2020
The O6-methyguanine-DNA methyltransferase inhibitor O6-benzylguanine enhanced activity of temozolomide + irinotecan against models of high-risk neuroblastomaAshly Hindle, Balakrishna Koneru, Monish Ram Makena, et al.
Pageof 22